J. Goldman & Co’s Aclaris Therapeutics ACRS Stock Holding History

J. Goldman & Co’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,456	Closed	-$78.5K	–	328
2023 Q3	$78.5K	Sell	11,456 -79,483	-87%	-$679K	﹤0.01%	335
2023 Q2	$943K	Buy	+90,939	New	+$823K	0.03%	257
2021 Q4	–	Sell	-177,740	Closed	-$3.2M	–	344
2021 Q3	$3.2M	Buy	177,740 +138,651	+355%	+$2.22M	0.16%	149
2021 Q2	$686K	Sell	39,089 -105,898	-73%	-$2.41M	0.03%	306
2021 Q1	$3.65M	Buy	144,987 +99,911	+222%	+$1.95M	0.12%	186
2020 Q4	$292K	Sell	45,076 -351,424	-89%	-$1.48M	0.01%	312
2020 Q3	$1.02M	Buy	+396,500	New	+$887K	0.07%	213
2017 Q3	–	Sell	-60,975	Closed	-$1.65M	–	331
2017 Q2	$1.65M	Buy	60,975 +12,100	+25%	+$329K	0.09%	194
2017 Q1	$1.46M	Buy	48,875 +6,702	+16%	+$193K	0.07%	230
2016 Q4	$1.15M	Buy	+42,173	New	+$1.08M	0.08%	213

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

J. Goldman & Co's ACRS Position: Q4 2023 in Review

J. Goldman & Co sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 11,456 shares — an estimated $78.5K sold.

J. Goldman & Co first reported a position in ACRS in Q4 2016 and held it in 10 quarters. The position peaked at $3.65M in Q1 2021. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

J. Goldman & Co reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 11,456 Aclaris Therapeutics shares in Q4 2023, an estimated $78.5K.
J. Goldman & Co first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 10 quarters.
J. Goldman & Co's Aclaris Therapeutics position peaked at $3.65M in Q1 2021.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.